Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development 2024-11-21 23:46
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024 2024-11-21 18:00
InxMed FAK Inhibitor Ifebemtinib Received Breakthrough Therapy Designation by China National Medical Products Administration for First-Line Non-Small Cell Lung Cancer (NSCLC) with KRAS G12C Mutation 2024-11-21 15:09
DP Technology and Lepu Biopharma Announce Milestone Collaboration: Leveraging Advanced Computational Methods to Accelerate ADC Drug Innovation 2024-11-21 13:01
Complete Genomics announces mpox virus amplicon sequencing panel at AMP 2024-11-21 01:01
Laekna Announces a Clinical Collaboration with Lilly to Develop LAE102, a Novel Monoclonal Antibody Targeting Activin Receptor Type 2A for The Treatment of Obesity 2024-11-20 22:00
Forging New Paths: Alfasigma Group and Fangzhou Inc. Chart a Course for Internet Healthcare 2024-11-20 10:38
Epigenic Therapeutics to Enter Clinical Development of EPI-003: A First-in-Class Epigenetic Inactivator for the Treatment of Chronic Hepatitis B 2024-11-20 07:20
Ractigen Therapeutics Announces FDA Orphan Drug Designation for RAG-21 for the Treatment of ALS 2024-11-19 21:26
Health2Sync Partners with Singapore Health Promotion Board and Abbott to Launch Innovative DigiCoach Program Tackling Pre-diabetes and Obesity 2024-11-19 21:00
Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study 2024-11-19 20:30
TAHO Pharmaceuticals Initiates U.S. Phase III Clinical Trial of TAH3311 Antithrombotic Oral Dissolving Film, Dosing First Subjects 2024-11-19 14:08
SK Biopharmaceuticals Seals 1st Actinium-225-Based Collaborative Research Agreement with Korea Institute of Radiological and Medical Sciences as Steps Toward Becoming Global Radiopharmaceutical Therapy Player 2024-11-19 08:00
Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024 2024-11-19 02:15
C Ray Therapeutics Completes Over $100 Million Series A+ Financing, Jointly Led by SCGC and TaiLong Capital 2024-11-18 22:00
Lunit Announces Collaboration with AstraZeneca to Develop AI-Powered Digital Pathology Risk Assessment Tools for NSCLC 2024-11-18 22:00
Biosion Announces Exclusive, Global License Agreement with Aclaris Therapeutics on two potential First-in-Class and Best-in-Class Immunology Assets 2024-11-18 21:50
Akeso Biopharma to Attend Jefferies London Healthcare Conference and Morgan Stanley 23rd Asia Pacific Summit 2024-11-18 21:16
WELLlife COVID-19/Influenza A&B Home Test on Sale for Black Friday and Cyber Monday 2024-11-18 21:00
TenNor Announces Positive Topline Results from Rifasutenizol Phase III Trial for H. pylori Infection 2024-11-18 19:00
1 2 3 4 5 165